These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16855847)

  • 1. Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
    Luft FC
    J Mol Med (Berl); 2006 Aug; 84(8):625-7. PubMed ID: 16855847
    [No Abstract]   [Full Text] [Related]  

  • 2. The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease.
    Rhyne J; Ryan MJ; White C; Chimonas T; Miller M
    J Mol Med (Berl); 2006 Aug; 84(8):647-50. PubMed ID: 16855848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CETP inhibition in perspective.
    Stock J
    Atherosclerosis; 2012 Feb; 220(2):325-8. PubMed ID: 22079329
    [No Abstract]   [Full Text] [Related]  

  • 5. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 8. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
    Kleber ME; Grammer TB; März W
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mulling over the odds of CETP inhibition.
    von Eckardstein A
    Eur Heart J; 2010 Feb; 31(4):390-3. PubMed ID: 20097704
    [No Abstract]   [Full Text] [Related]  

  • 10. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CETP inhibitors to increase HDL cholesterol levels.
    Tall AR
    N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CETP inhibitor].
    Inazu A; Mabuchi H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():671-4. PubMed ID: 11347151
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
    Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
    J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
    Okamoto H; Miyai A; Sasase T; Furukawa N; Matsushita M; Nakano T; Nakajima K
    Clin Chim Acta; 2007 Jan; 375(1-2):92-8. PubMed ID: 16859664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians.
    van der Steeg WA; Hovingh GK; Klerkx AH; Hutten BA; Nootenboom IC; Levels JH; van Tol A; Dallinga-Thie GM; Zwinderman AH; Kastelein JJ; Kuivenhoven JA
    J Lipid Res; 2007 Mar; 48(3):674-82. PubMed ID: 17192423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
    Shin HJ; McCullough PA
    Nephron Clin Pract; 2014; 127(1-4):158-64. PubMed ID: 25343842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.